Allovir Inc
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6,… Read more
Allovir Inc (ALVR) - Total Liabilities
Latest total liabilities as of December 2024: $5.24 Million USD
Based on the latest financial reports, Allovir Inc (ALVR) has total liabilities worth $5.24 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allovir Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Allovir Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Allovir Inc Competitors by Total Liabilities
The table below lists competitors of Allovir Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Auris Minerals Ltd
AU:AUR
|
Australia | AU$253.26K |
|
New Century Logistics (BVI) Limited Ordinary Shares
NASDAQ:NCEW
|
USA | $1.19 Million |
|
Alba Mineral Resources plc
PINK:ALBAF
|
USA | $403.00K |
|
Unlimited Travel Group UTG AB (publ)
ST:UTG
|
Sweden | Skr468.01 Million |
|
Born Inc
PINK:BRRN
|
USA | $85.17K |
|
Retractable Technologies Inc
NYSE MKT:RVP
|
USA | $69.65 Million |
|
Eurotel SA
WAR:ETL
|
Poland | zł96.72 Million |
|
Seoul Electronics & Telecom Co. Ltd
KQ:027040
|
Korea | ₩42.33 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Allovir Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allovir Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allovir Inc (2018–2024)
The table below shows the annual total liabilities of Allovir Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.24 Million | -88.36% |
| 2023-12-31 | $45.02 Million | -14.36% |
| 2022-12-31 | $52.56 Million | -14.30% |
| 2021-12-31 | $61.33 Million | +245.37% |
| 2020-12-31 | $17.76 Million | -90.70% |
| 2019-12-31 | $190.93 Million | +241.30% |
| 2018-12-31 | $55.94 Million | -- |